# Sentinel Lymph Node Biopsy

> Sentinel lymph node biopsy for NEET-SS Surgical Oncology: dual-tracer technique, Z0011 and AMAROS rules, false-negative control and melanoma mapping thresholds.

- Canonical URL: https://prepelephant.com/topics/neet-ss/surgical-oncology/sentinel-lymph-node-ss
- Exam / course: NEET-SS · Subject: Surgical Oncology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Sentinel Lymph Node Biopsy", PrepElephant, https://prepelephant.com/topics/neet-ss/surgical-oncology/sentinel-lymph-node-ss

## Direct answer

The sentinel node is the first lymph node receiving drainage from a tumour, and mapping it lets the surgeon stage the whole basin by removing one or two nodes instead of fifteen. Dual-tracer identification — radioisotope plus blue dye — succeeds in over 95 per cent of axillas with a false-negative rate near 5 per cent when technique is disciplined. The technique's recent contribution has been subtractive rather than additive: Z0011 and AMAROS in breast cancer and MSLT-II in melanoma have abolished the automatic completion dissection that once followed a positive sentinel node. Tracer choice, node counts and the response to a positive result all shift with tumour type, treatment sequence and pregnancy.

## What you must remember

- **Tracers:** Tc-99m-labelled colloid or tilmanocept, blue dye (isosulfan blue; methylene blue is widely used in India on cost grounds), and indocyanine green with near-infrared imaging.
- **Pregnancy:** blue dye is avoided; radioisotope mapping alone is acceptable because fetal dose is negligible. Isosulfan blue carries roughly 1 per cent anaphylaxis risk.
- **Nodal burden language:** isolated tumour cells ≤0.2 mm, micrometastases >0.2–2 mm, macrometastases >2 mm — management differs at each threshold.
- **ACOSOG Z0011:** one to two positive sentinel nodes, T1–2 cN0, breast conservation with whole-breast radiotherapy, no neoadjuvant chemotherapy — axillary dissection may be omitted.
- **AMAROS:** axillary radiotherapy equals dissection for a positive sentinel node with less lymphoedema; IBCSG 23-01 showed dissection adds nothing for micrometastases.
- **Melanoma:** offer sentinel biopsy above 0.8 mm thickness or for any ulcerated thin tumour; MSLT-II and DeCOG support ultrasound surveillance over completion dissection when the node is positive.
- **After neoadjuvant chemotherapy** converting cN1 to cN0, the pre-chemotherapy clipped node must be excised with dual tracer and at least three nodes harvested (Z1071, SENTINA), or the false-negative rate climbs steeply.
- **Lymphoedema:** 15–30 per cent after axillary dissection versus under 10 per cent after sentinel biopsy — the strongest argument for staging before cutting.

## Working through a positive sentinel node

A 48-year-old woman with a 2.5 cm ER-positive carcinoma, clinically node-negative, undergoes wide local excision with dual-tracer sentinel biopsy; one of two nodes carries a 4 mm metastasis. Every Z0011 condition is met — breast conservation, no neoadjuvant, one positive node — so no axillary dissection is done; whole-breast radiotherapy plus endocrine therapy covers the basin. Now change one variable: she chooses mastectomy. The Z0011 evidence evaporates because there is no whole-breast radiotherapy to sterilise residual axillary disease; the options become completion dissection or axillary radiotherapy on AMAROS grounds. Change a second variable: she presented cN1, received neoadjuvant chemotherapy and converted — sentinel biopsy is still permissible, but only with the clipped node retrieved and three or more nodes sampled. The technique is constant; the evidence moves with each line of the vignette, which is precisely how the examination asks it.

## How the exam frames it

Questions rarely ask what a sentinel node is; they quote a trial and test whether you know its boundary conditions. The recurring traps are Z0011 applied to mastectomy or post-neoadjuvant patients (both excluded from the trial), a 0.2 mm focus labelled micrometastasis when it is isolated tumour cells, and methylene blue causing a spurious low pulse-oximetry reading — a favourite image-based distractor. A classic viva sequence is breast cancer in pregnancy: which tracer is safe, and the expected answer is radioisotope alone, blue dye withheld.

## Frequently asked questions

### Which tracer is used for sentinel node biopsy in pregnancy?
Radioisotope alone is considered acceptable because fetal radiation dose is negligible; blue dyes are avoided because of anaphylaxis risk and fetal concerns.

### What did ACOSOG Z0011 establish?
In cN0 T1–2 breast cancer treated with conservation and whole-breast radiotherapy, omitting axillary dissection for one or two positive sentinel nodes did not worsen survival or regional control.

### When does a positive sentinel node still require axillary dissection?
After mastectomy without planned radiotherapy, with three or more involved sentinel nodes, gross residual nodal disease, or when Z0011 criteria such as no-neoadjuvant treatment are not met.

### How is sentinel biopsy performed after neoadjuvant chemotherapy?
Clip the biopsy-proven node before chemotherapy; at surgery use dual tracer, retrieve the clipped node and at least three nodes total — the safeguards that keep the false-negative rate acceptable.

### What size defines a micrometastasis?
Greater than 0.2 mm up to 2 mm; deposits of 0.2 mm or less are isolated tumour cells, and deposits beyond 2 mm are macrometastases.

### What is the role of sentinel node biopsy outside breast cancer?
In melanoma it is offered above 0.8 mm thickness or with ulceration, and in endometrial cancer indocyanine-green mapping (FIRES trial) has become a staging alternative to systematic lymphadenectomy.